Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4564268
Max Phase: Preclinical
Molecular Formula: C17H14F6N4O2
Molecular Weight: 420.31
Molecule Type: Unknown
Associated Items:
ID: ALA4564268
Max Phase: Preclinical
Molecular Formula: C17H14F6N4O2
Molecular Weight: 420.31
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Nc1c(F)c(NCc2ncc(C(F)(F)F)cc2F)cc(F)c1NC(=O)OC1CC1
Standard InChI: InChI=1S/C17H14F6N4O2/c18-9-3-7(17(21,22)23)5-25-12(9)6-26-11-4-10(19)15(14(24)13(11)20)27-16(28)29-8-1-2-8/h3-5,8,26H,1-2,6,24H2,(H,27,28)
Standard InChI Key: YAUVRZGKIRPKAW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 420.31 | Molecular Weight (Monoisotopic): 420.1021 | AlogP: 4.42 | #Rotatable Bonds: 5 |
Polar Surface Area: 89.27 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.14 | CX Basic pKa: 1.93 | CX LogP: 2.83 | CX LogD: 2.83 |
Aromatic Rings: 2 | Heavy Atoms: 29 | QED Weighted: 0.49 | Np Likeness Score: -1.09 |
1. Liu R, Tzounopoulos T, Wipf P.. (2019) Synthesis and Optimization of Kv7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity., 10 (6): [PMID:31223450] [10.1021/acsmedchemlett.9b00097] |
Source(1):